MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpeds.2025.114664

Медицинская библиотека · The Journal of pediatrics · 2025

The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.

Kronn David, Davison James, Broomfield Alexander, Brassier Anaïs, Labarthe François, Hahn Si Houn, Kumada Satoko, Ohki Hirotaka, Prakalapakorn Sasapin Grace, Wilson Catherine, Haack Kristina An, Huynh-Ba Olivier, Richards Susan, Sparks Susan, Tammireddy Swathi, Zhou Tianyue, Chien Yin-Hsiu, Kishnani Priya S, Mini-COMET investigators

СтатьяКлиническое исследование II фазыМногоцентровое исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

OBJECTIVE

To evaluate the long-term safety and efficacy of avalglucosidase alfa in children with infantile-onset Pompe disease experiencing clinical decline (cohorts 1 and 2) or suboptimal response (cohort 3) to prestudy alglucosidase alfa.

STUDY

DESIGN

The Mini-COMET clinical trial, a phase 2, open-label, ascending-dose, 3-cohort study, has a 25-week primary analysis period (PAP) and an extension treatment period (ETP). In the PAP, cohorts 1 (n = 6) and 2 (n = 5) received avalglucosidase alfa 20 or 40 mg/kg every other week (qow), respectively. Cohort 3 received avalglucosidase alfa 40 mg/kg qow (n = 5) or alglucosidase alfa (prestudy [>6 months] stable dose: 20 mg/kg qow to 40 mg/kg weekly; n = 6). All children completed the PAP and entered the ETP. Children receiving avalglucosidase alfa in the PAP continued the same dose in the ETP. Those receiving alglucosidase alfa in the PAP received avalglucosidase alfa 40 mg/kg qow in the ETP.

RESULTS

At baseline, children were 1-12 years old. Interim data (≥97 weeks) are presented from all 22 children, 20 receiving avalglucosidase alfa 40 mg/kg qow and 2 receiving 20 mg/kg qow in the ETP. Among the 6 who received 20 mg/kg qow avalglucosidase alfa in PAP (cohort 1), 4 had their dose increase to 40 mg/kg qow because of further clinical decline in the ETP. No child died or discontinued at data cutoff. PAP and ETP safety profiles were similar; no treatment-related serious or severe treatment-emergent adverse events occurred. Avalglucosidase alfa was well-tolerated, with no increased safety risk or immunogenicity concerns post-treatment switch. Echocardiography revealed persistent left ventricular mass z score normalization. Compared with baseline, biomarkers of Pompe disease burden decreased, and motor function improved or stabilized.

CONCLUSIONS

Results support the positive clinical impact of long-term avalglucosidase alfa in children with infantile-onset Pompe disease.

TRIAL REGISTRATION: ClinicalTrials.gov: NCT03019406.

Для цитирования: Kronn David, Davison James, Broomfield Alexander, Brassier Anaïs, Labarthe François, Hahn Si Houn, Kumada Satoko, Ohki Hirotaka, Prakalapakorn Sasapin Grace, Wilson Catherine, Haack Kristina An, Huynh-Ba Olivier, Richards Susan, Sparks Susan, Tammireddy Swathi, Zhou Tianyue, Chien Yin-Hsiu, Kishnani Priya S, Mini-COMET investigators. The Mini-COMET Clinical Trial: Safety and Efficacy of Avalglucosidase Alfa after 97 Weeks of Treatment in Children with Infantile-Onset Pompe Disease Previously Treated with Alglucosidase Alfa.. The Journal of pediatrics. 2025. DOI: 10.1016/j.jpeds.2025.114664.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.